ORGENESIS INC. (OTCMKTS:ORGS) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02 Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers
As reportedin Item 5.07 of this Form 8-K Report, the stockholders
of Orgenesis Inc. (the Company) approved the 2017 Equity
Incentive Plan (the 2017 Plan) at the Companys 2017 Annual
Meeting of Stockholders (the 2017 Annual Meeting).
The description of the material terms of the Plan included in the
Companys definitive proxy statement filed with the Securities and
Exchange Commission on April 1, 2016 (the Companys Proxy
Statement) for the 2016 Annual Meeting is incorporated by
reference in this Form 8-K. Such description does not purport to
be complete and is qualified in its entirety by reference to the
full text of each of the Plan which is filed as Annex A in the
Companys Proxy Statement and is also incorporated herein by
reference.
Item 5.07 Submission of Matters to a Vote of Security
holders
On May 11, 2017, the Company held its annual meeting of
stockholders at 10:00 a.m. at the offices of Pearl Cohen Zedek
Latzer Baratz LLP at 1500 Broadway, New York, NY. As of March 20,
2017, the record date for the 2017 Annual Meeting, there were
114,579,381 shares of common stock issued and outstanding. A
quorum of common stockholders, present in person or by proxy,
representing 87,488,558 shares of common stock, or 76% of the
shares entitled to vote, was present at the 2017 Annual Meeting.
The final voting results of the 2017 Annual Meeting are set forth
below.
1. Proposal to elect directors to serve until the 2018 Annual
Meeting of Stockholders.
The Companys stockholders elected each of the Companys six
nominees for director to serve a term of one year to expire at
the 2018 annual meeting of stockholders or until their respective
successors are duly elected and qualified, as set forth below:
| Name | Votes For | Votes Withheld | Abstain | Broker Non-Votes |
| Vered Caplan | 59,179,775 | 25,032,687 | 11,950 | 3,264,146 |
| Guy Yachin | 59,173,105 | 25,039,357 | 11,950 | 3,264,146 |
| David Sidransky | 59,179,775 | 25,032,687 | 11,950 | 3,264,146 |
| Yaron Adler | 59,173,105 | 25,039,357 | 11,950 | 3,264,146 |
| Hugues Bultot | 59,179,775 | 25,032,687 | 11,950 | 3,264,146 |
| Ashish Nanda | 59,173,105 | 25,039,357 | 11,950 | 3,264,146 |
2. Proposal to adopt the 2017 Plan.
The Companys stockholders approved the Companys 2016 Plan, as set
forth below:
| Votes For | Votes Against | Abstain | Broker Non-Votes |
| 59,097,807 | 25,104,882 | 21,813 | 3,264,056 |
3. Proposal to approve, in a nonbinding advisory vote, the
compensation of the Companys named executive officers.
The Companys stockholders approved, in a nonbinding and advisory
vote, the compensation of its named executive officers as
described in the Companys Proxy Statement, as set forth below:
| Votes For | Votes Against | Abstain | Broker Non-Votes |
| 59,122,006 | 25,078,518 | 23,888 | 3,264,146 |
4. The results of the nonbinding advisory vote of the Companys
stockholders with respect to the frequency of nonbinding advisory
votes on executive compensation, are as set forth below:
| One Year | Two Years | Three Years | Abstain | Broker Non-Votes |
| 25,645,651 | 18,200 | 58,537,487 | – | 3,287,220 |
All proposals received the requisite number of votes and were
approved.
About ORGENESIS INC. (OTCMKTS:ORGS)
Orgenesis Inc. is a regenerative therapy company. The Company operates through two segments: Contract Development and Manufacturing Organization (CDMO) and Cellular Therapy Business (CTB). The CDMO activity is operated by the Company’s subsidiary, MaSTherCell SA, which specializes in cell therapy development for advanced medicinal products. MaSTherCell is providing two types of services to its customers: process and assay development services and good manufacturing practice (GMP) contract manufacturing services. The CTB activity is based on its technology that demonstrates the capacity to induce a shift in the developmental fate of cells from the liver and differentiating (converting) them into pancreatic beta cell-like insulin producing cells for patients with Type I Diabetes. It intends to advance a product that combines cell-based therapy and regenerative medicine, Autologous Insulin Producing (AIP) cells, into clinical development. ORGENESIS INC. (OTCMKTS:ORGS) Recent Trading Information
ORGENESIS INC. (OTCMKTS:ORGS) closed its last trading session 00.000 at 0.700 with 2,000 shares trading hands.